|1.||Yang, Wenying: 7 articles (01/2014 - 05/2008)|
|2.||Kawamori, Ryuzo: 6 articles (04/2013 - 01/2005)|
|3.||Sharma, S K: 5 articles (01/2013 - 12/2007)|
|4.||Heller, Simon: 4 articles (12/2013 - 04/2007)|
|5.||Shestakova, M: 4 articles (03/2008 - 01/2006)|
|6.||Lindholm, A: 4 articles (11/2001 - 07/2000)|
|7.||Mersebach, Henriette: 3 articles (08/2014 - 03/2010)|
|8.||Shah, Siddharth: 3 articles (06/2014 - 04/2013)|
|9.||Bode, Bruce: 3 articles (12/2013 - 01/2007)|
|10.||Haddad, Jihad: 3 articles (12/2013 - 06/2013)|
|1.||Type 2 Diabetes Mellitus (MODY)
03/01/2008 - "The use of BIAsp 30 monotherapy or in combination with OADs in clinical practice was effective and safe in patients with poorly controlled type 2 diabetes mellitus."
03/01/2013 - "This is an open-label, non-randomized, non-interventional, observational study of safety and efficacy of BiAsp 30, enrolling 2223 patients with type 2 diabetes mellitus. "
12/01/2007 - "In this observational study, in the type 2 diabetes mellitus patients who were poorly controlled on BHI, glycaemia improved when transferred to BIAsp30, and a lower incidence or rate of hypoglycaemia was observed in these patients."
01/01/2003 - "However, the long-term efficacy of BIAsp30 was similar to that of BHI30 after 2 years in a randomized, nonblind trial in patients with type 2 diabetes mellitus. "
01/01/2002 - "However, the long-term efficacy of BIAsp30 was similar to that of BHI30 after 2 years in a randomised, nonblind trial in patients with type 2 diabetes mellitus. "
|2.||Hypoglycemia (Reactive Hypoglycemia)
06/01/2013 - "All age-groups showed improved glycemic control and reduced risk of hypoglycemia when starting/switching to insulin aspart therapy within a basal-bolus regimen; this may be particularly important for elderly patients given their greater risk of hypoglycemia versus younger patients."
05/01/2008 - "Biphasic insulin aspart 30 three times daily is more effective than a twice-daily regimen, without increasing hypoglycemia, in Chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetes drugs."
01/01/2014 - "In this subgroup analysis of the A1chieve study, biphasic insulin aspart 30 improved glycemic control with low risk of hypoglycemia."
12/01/2014 - "The FullSTEP trial demonstrated that stepwise addition (SWA) of bolus insulin aspart was non-inferior to full basal-bolus (FBB) therapy and reduced the rate of hypoglycemia. "
11/01/2010 - "The aim of the study was to investigate the risk of hypoglycemia after the use of insulin aspart in basal-bolus therapy in patients with type 1 and 2 diabetes. "
|3.||Type 1 Diabetes Mellitus (Autoimmune Diabetes)
07/01/2005 - "This multinational, 16-week, open, parallel group trial included 400 people with Type 1 diabetes mellitus (DM) randomized to IDet either morning and before dinner (IDetmorn+din) or morning and bedtime (IDetmorn+bed), or to NPH morning and bedtime (NPHmorn+bed), all in combination with mealtime insulin aspart (IAsp). "
09/01/2008 - "The objective of this review was to evaluate evidence-based information using biphasic insulin aspart 30 in the treatment of type 1 diabetes mellitus. "
09/01/2008 - "Biphasic insulin aspart 30 for the treatment of type 1 diabetes mellitus."
01/01/2002 - "In most randomised, nonblind clinical trials in patients with type 1 diabetes mellitus, insulin aspart administered immediately before meals resulted in significantly lower mean glycosylated haemoglobin A(1c ) (HbA(1c)) levels than regular human insulin (usually administered 30 minutes before a meal). "
02/01/2011 - "In random order, ten patients with Type 1 diabetes mellitus received insulin aspart with subcutaneous bolus insulin injection, continuous subcutaneous insulin infusion and continuous intravenous insulin infusion. "
03/01/2014 - "BIAsp 30 use is associated with slightly larger weight gain but no rise in risk of severe hypoglycaemic episodes."
03/01/2014 - "Twice-daily administration of BIAsp 30 resulted in larger weight gain [2 RCTs; WMD (95% CI) = 1.78 kg (1.04; 2.52)]. "
01/01/2009 - "Adding BIAsp30 to met in obese patients with T2DM results in better glycemic control and less weight gain than adding BHI30."
02/01/2007 - "Treatment with biphasic insulin aspart was associated with weight gain and lower risk of adverse gastrointestinal events. "
01/01/2013 - "Initiating insulin therapy with or switching to BIAsp 30 in patients with poor glycaemic control leads to an improvement in glycaemic profile with no major hypoglycaemia or clinically significant weight gain. "
|5.||Body Weight (Weight, Body)
01/01/2011 - "Total body weight increase by 2.0±2.6 kg. The initiation and titration protocol with BIAsp 30 improved glycaemic control, and increased the number of patients with the achievement of glycaemic goals."
01/01/2009 - "Body weight gain was minimal with BIAsp30, and treatment satisfaction among these patients appeared to be high."
11/01/2007 - "Mean body weight increased significantly from baseline with both BIAsp 30 TID and BIAsp 30 BID + MET (+1.71 and +1.50 kg, respectively; both, P < 0.001), and decreased significantly in the OAD group (-0.75 kg; P = 0.003). "
11/01/2007 - "The addition of a third injection of BIAsp 30 substantially improved HbA1c and decreased body weight and the incidence of hypoglycemia in 12 patients with type 2 diabetes who did not achieve optimal glycemic control on a BID regimen."
10/05/2007 - "Subcutaneous absorption is accelerated by the monomeric conformation of insulin Aspart, which provides good glycemic control with a lower risk of hypoglycemia and less body weight increase. "
|2.||insulin LISPRO (Humalog)
|3.||insulin aspart (NovoLog)
|5.||glargine (insulin glargine)
|9.||insulin detemir (Levemir)